Previous article Next article

The EU Commission prohibits the acquisition of a company producing an novel blood testing technology by a large biotech company on the grounds that it would allow the combination to foreclose competition in a innovative and important market (GRAIL / Illumina)

Mergers: Commission prohibits acquisition of GRAIL by Illumina* The European Commission has prohibited, under the EU Merger Regulation, the implemented acquisition of GRAIL by Illumina. The merger would have stifled innovation, and reduced choice in the emerging market for blood-based early cancer detection tests. Illumina did not offer remedies sufficient to address these concerns. Executive Vice-President Margrethe Vestager, in charge of competition policy, said: “Today we prohibited Illumina's implemented acquisition of GRAIL. In a race with other companies, GRAIL is developing a blood-based early cancer detection test. If successful, these tests will revolutionise our fight against cancer and help to save millions of lives. Illumina is currently the only credible supplier of a

Access to this article is restricted to subscribers

Already Subscribed? Sign-in

Access to this article is restricted to subscribers.

Read one article for free

Sign-up to read this article for free and discover our services.

 

PDF Version

Author

Quotation

European Commission, The EU Commission prohibits the acquisition of a company producing an novel blood testing technology by a large biotech company on the grounds that it would allow the combination to foreclose competition in a innovative and important market (GRAIL / Illumina), 6 September 2022, e-Competitions Preview, Art. N° 108573

Visites 33

All issues

  • Latest News issue 
  • All News issues
  • Latest Special issue 
  • All Special issues